Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

54.25 +0.13 (+0.24%)
Streaming Delayed Price Updated: 3:59 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
News headline image
Roche's New COVID-19 Point Of Care Test Scores FDA Emergency Use Nod ↗
The FDA has granted Emergency Use Authorization (EUA) to Roche Holding AG's (OTC: RHHBY) Cobas SARS-CoV-2 Nucleic acid test for use on the Cobas Liat... 
Via Benzinga
News headline image
Amneal's Avastin-Referred Biosimilar Under FDA Review For Colorectal Cancer ↗
The FDA has accepted for review Amneal Pharmaceuticals Inc's (NYSE: AMRX) marketing application seeking approval for Bevacizumab, under Section 351(k) pathway... 
Via Benzinga
News headline image
Synlogic, Roche Ink Research Pact For Inflammatory Bowel Disease Therapy ↗
Synlogic Inc (NASDAQ: SYBX) has entered into a research collaboration agreement with Roche Holding AG (OTC: RHHBY) for the discovery of Synthetic Biotic... 
Via Benzinga
News headline image
Atea Pharma Secures AT-527-Related Milestone Payment Of $50M From Roche ↗
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has achieved a development milestone associated with AT-527 and expects to receive a related payment under its license... 
Via Benzinga
News headline image
Continued Uncertainty ↗
Fear of another Fukushima yesterday late in the market day led to a rush out of energy-related shares, which included many without any nuclear risk at all. 
Via Talk Markets
News headline image
Stock Profile: Roche Holding AG ADR ↗
Roche maintains a healthy balance sheet with $13.9 billion in cash and investments and $12.5 billion in long-term debt as of 12/31/2020. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
News headline image
Dreary Day ↗
Another dreary day and a renewed boost for cryptocurrency - and away from the classic inflation hedge, gold. 
Via Talk Markets
News headline image
JNJ's Imbruvica, AbbVie's Venclexta Combo Achieves Progression-Free Survival Of 78.4% Versus Gazyva-Chemo Cocktail In Leukemia Patients ↗
A combination of Johnson & Johnson’s (NYSE: JNJ) Imbruvica and AbbVie Inc (NYSE: ABBV) - Roche Holding AG’s (OTC: RHHBY) Venclexta/... 
Via Benzinga
News headline image
Happy Friday ↗
The inflation risk is being ignored by the US market now that there will probably not be a tax increase and may be higher prices for longer. 
Via Talk Markets
News headline image
AbbVie-Roche's Venclexta Shows Progression-Free Survival Of 74% In CLL Patients After Three Years Treatment ↗
Genentech, a unit of Roche Holdings AG (OTC: RHHBY), and its collaborating partner AbbVie Inc (NYSE: ABBV) have announced long-term follow-up data ... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,... 
Via Benzinga
News headline image
Genentech Announces Data at EHA2021 Reinforcing Efficacy of Venclexta Combinations in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
From Genentech
Via Business Wire
News headline image
New Genentech Data for Evrysdi (risdiplam) Show Improved Motor Function in Pre-Symptomatic Babies After One Year and Confirm Safety Profile in Previously Treated People With Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
News headline image
Unheeding Markets ↗
Today oil prices rose over $70. 
Via Talk Markets
News headline image
With Aduhelm Approval Behind Biogen, 5 Catalysts For Investors To Watch ↗
Biogen Inc. (NASDAQ: BIIB) made history of sorts with the FDA approval for its Alzheimer's treatment Aduhelm. Notwithstanding the still-raging debate over the decision, an... 
Via Benzinga
News headline image
Wednesday News And Catch-Up ↗
Today the US market resumed its attempt to hit a new record for the S&P 500 and Nasdaq, but not the DJIA. 
Via Talk Markets
Topics Stocks
News headline image
Juvenile Investing Mob ↗
Tech stocks did well in Europe but not in the US. The data are unconvincing. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7) Agios Pharmaceuticals, Inc... 
Via Benzinga
News headline image
FDA surprise ↗
The big news out of China is that its import purchases of copper and iron sagged last month because its export markets are far less strong than earlier this year. 
Via Talk Markets
News headline image
Biogen Wins Landmark Alzheimer's Approval: 5 Things To Know About Aducanumab ↗
The FDA approved Biogen's Alzheimer's treatment, aducanumab, on Monday — though Biogen stock remained halted into the long-awaited decision. 
Via Investor's Business Daily
News headline image
Argenx Regains Global Rights from Johnson & Johnson to Blood Cancer Candidate Cusatuzumab ↗
Johnson & Johnson (NYSE: JNJ) has walked away from a $1.6 billion blood cancer candidate deal with Argenx SE (NASDAQ: ARGX) for the CD70-targeting... 
Via Benzinga
News headline image
A Better Switch ↗
Today the US market decided to rise because President Biden is pondering not linking his infrastructure project to a corporate tax increase. 
Via Talk Markets
News headline image
Surface Oncology, Roche Team Up to Develop SRF388 Combo Therapy for Liver Cancer ↗
Surface Oncology (NASDAQ: SURF) has entered into a clinical trial collaboration with Roche Holdings AG (OTC: RHHBY) to evaluate former's SRF388, anti... 
Via Benzinga
News headline image
Genentech Presents Latest Advances With Immunotherapies in Non-Hodgkin’s Lymphoma
From Genentech
Via Business Wire
News headline image
Fan Hit ↗
The 10-yr US treasury yield rose to 1.6% again. Later in the day, a rally was attempted, mostly for the meme shares. 
Via Talk Markets
News headline image
Constellation Pharma Rockets On Word Of $1.7 Billion MorphoSys Takeover ↗
MorphoSys announced its $1.7 billion plan to acquire cancer treatment biotech Constellation on Wednesday and CNST stock rocketed to a four-month high. 
Via Investor's Business Daily
News headline image
Biogen, Bio-Thera's Biosimilar Referencing Tocilizumab Meets Primary Endpoints In Late-Stage Study ↗
Biogen Inc (NASDAQ: BIIB) and China's Bio-Thera Solutions Ltd have announced results from the Phase 3 study of BAT1806, a proposed biosimilar referencing... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25) ESSA Pharma Inc. (NASDAQ:... 
Via Benzinga
News headline image
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.